ストックスクリーナーアプリを入手
0.4192
11.58%
0.0435
アフターアワーズ：
.43
0.0108
+2.58%
前日終値:
$0.3757
開ける：
$0.39
24時間の取引高:
1.32M
Relative Volume:
0.72
時価総額：
$28.34M
収益：
-
当期純損益:
$-17.78M
株価収益率:
-0.7633
EPS:
-0.5492
ネットキャッシュフロー:
$-10.52M
1週間 パフォーマンス:
+48.18%
1か月 パフォーマンス:
+84.59%
6か月 パフォーマンス:
-27.01%
1年 パフォーマンス:
-64.17%
1日の値動き範囲:
$0.38
$0.439
1週間の範囲:
$0.30
$0.4799
52週間の値動き範囲:
$0.2201
$1.53
Fibrobiologics Inc Stock (FBLG) Company Profile
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.4192 | 25.40M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-24 | 開始されました | Maxim Group | Buy |
Fibrobiologics Inc (FBLG) 最新ニュース
FibroBiologics completes site onboarding for diabetic ulcer trial - Investing.com
FibroBiologics completes site onboarding for diabetic ulcer trial By Investing.com - Investing.com Nigeria
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Bitget
FibroBiologics Completes Site Onboarding for Phase 1/2 - GlobeNewswire
CEO Doubles Down on FibroBiologics With Bold Insider Stock Purchase - TipRanks
CFO’s Bold Insider Buy Sparks Fresh Buzz Around FibroBiologics Stock - TipRanks
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock By Investing.com - Investing.com Australia
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock - Investing.com
FibroBiologics (FBLG) CFO purchases 70,000 shares in open-market trade - Stock Titan
Insider Makes Bold New Bet on FibroBiologics Stock - TipRanks
FBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FibroBiologics Jumps 22% On New Osteoporosis Patent, Stock Up - Nasdaq
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG - Investing.com
FibroBiologics receives patent for osteoporosis cell therapy - Investing.com
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG By Investing.com - Investing.com South Africa
FibroBiologics, Inc. announces issuance of U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis - marketscreener.com
Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis - TradingView
New fibroblast cell therapy patent targets osteoporosis - Stock Titan
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Sahm
FBLG: Ready to Transition to Clinical-Stage Company - Smartkarma
FBLG Technical Analysis & Stock Price Forecast - Intellectia AI
FibroBiologics to Present at the BIO Investment & Growth Summit - Bitget
H.C. Wainwright cuts FibroBiologics stock price target to $4 By Investing.com - Investing.com Canada
H.C. Wainwright cuts FibroBiologics stock price target to $4 - Investing.com Nigeria
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update - Bitget
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
FibroBiologics (FBLG) expands fibroblast-based cell therapy pipeline - Stock Titan
FibroBiologics gets Nasdaq extension to meet listing rules - Investing.com Australia
FibroBiologics gets Nasdaq extension to meet listing rules By Investing.com - Investing.com South Africa
FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances - TipRanks
FibroBiologics shareholders approve reverse stock split and warrant share issuances - Investing.com Nigeria
FibroBiologics (NASDAQ: FBLG) investors approve reverse split and warrant shares - Stock Titan
FibroBiologics Granted Extension by Nasdaq to Regain Compliance - Bitget
FBLG PE Ratio & Valuation, Is FBLG Overvalued - Intellectia AI
Weekly Recap: Is FibroBiologics Inc stock overvalued or fairly pricedJuly 2025 Technicals & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Earnings & Real-Time Market Sentiment Reports - mfd.ru
How FibroBiologics Inc. stock reacts to inflationary pressuresJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - mfd.ru
Should I add FibroBiologics Inc. stock to my portfolio2025 Earnings Impact & AI Based Buy/Sell Signal Reports - mfd.ru
FBLG Should I Buy - Intellectia AI
Aug Drivers: Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Long-Term Safe Investment Plans - baoquankhu1.vn
What’s the fair value of FibroBiologics Inc. stockJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
FibroBiologics CEO Pete O’Heeron to Speak at A4LI's H-SPAN Summit on Longevity Science - Quiver Quantitative
Longevity policy summit taps FibroBiologics CEO for main stage talk - Stock Titan
Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
FibroBiologics Faces Nasdaq Delisting Review After Noncompliance - TipRanks
FibroBiologics Received Notice of Delisting - TradingView
FibroBiologics Secures Canadian Patent for Innovative Cachexia Treatment Using Fibroblast Cells - Quiver Quantitative
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia - ChartMill
FibroBiologics (NASDAQ:FBLG) Shares Down 1.6% – What’s Next? - Defense World
Fibrobiologics Inc (FBLG) 財務データ
収益
当期純利益
現金流量
EPS
Fibrobiologics Inc (FBLG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
| Khoja Hamid | Chief Scientific Officer |
May 27 '25 |
Buy |
0.84 |
20,000 |
16,800 |
31,250 |
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):